Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance

NCT ID: NCT06107088

Last Updated: 2024-07-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-20
• Study Completion Date: 2024-07-10

Brief Summary

The goal of this clinical trial is to test whether a new combination of lactase and bacterial strain (L. Salivarius DSM 34078) can provide longer lasting beneficial effects on lactose digestion and gastrointestinal symptoms compared to lactase alone in people with lactose intolerance.

Detailed Description

Participants will attend 3 visits (V0, V1, V2). Visit 0 is a screening/baseline visit (5 to 10 days before Visit 1), where participants will be checked for inclusion and exclusion criteria, and undergo a lactose challenge (drink a cup of lactose containing water) followed by a hydrogen breath test (HBT) and Carbohydrate Perception Questionnaire (CPQ) measured at intervals over 3 hours. At Visit 1, eligible participants are randomized into one of the four study arms: Lactase and bacterial strain combination in a capsule; lactase and bacterial strain combination in separate capsules, lactase only, or placebo. Each Visit 1 and Visit 2 takes about 8 hours, where participants take the investigational product (IP) before the first lactose challenge (with first HBT and first CPQ for 3 hours), followed by a 2-hour break with standardized meal provided, and undergo a second lactose challenge (with second HBT and second CPQ for another 3 hours). Visit 2 is scheduled one week after Visit 1, where participants take the IP once daily at home for a week and fill in a diary between Visit 1 and 2. Stool samples are collected at Visit 1 and 2.

Conditions

Lactose Intolerance

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Test product1

1 capsule 'lactase-bacterial strain combination' and 1 capsule placebo, once a day, one week

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo

Active 2

Intervention Type: DIETARY_SUPPLEMENT

lactase-bacterial strain combination

Test product2

1 capsule lactase and 1 capsule bacterial strain, once a day, one week

Group Type: EXPERIMENTAL

Active 3

Intervention Type: DIETARY_SUPPLEMENT

bacterial strain alone

Active 1

Intervention Type: DIETARY_SUPPLEMENT

lactase enzyme

Comparator

1 capsule lactase and 1 capsule placebo, once a day, one week

Group Type: ACTIVE_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo

Active 1

Intervention Type: DIETARY_SUPPLEMENT

lactase enzyme

Placebo

2 capsules placebo, once a day, one week

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo

Interventions

Active 3

bacterial strain alone

Intervention Type: DIETARY_SUPPLEMENT

Placebo

placebo

Intervention Type: DIETARY_SUPPLEMENT

Active 1

lactase enzyme

Intervention Type: DIETARY_SUPPLEMENT

Active 2

lactase-bacterial strain combination

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Men and women from 18 to 65 years old

2. Self-reported:

• previously diagnosed lactose intolerance or
• presumed lactose intolerance, defined as GI complaints upon intake of lactose-containing food/beverage (such as abdominal pain, distension, bloating, flatulence, nausea, diarrhea), when no lactase or lactase-containing product has been used by the subject

3. Lactose maldigestion, confirmed by hydrogen breath test during lactose challenge at V0 (increase in H2 concentration of ≥ 20 parts per million (ppm) compared to value at t=0, during first 3 hours upon challenge)

4. Generally in good health as per investigator's judgement

5. Subject's ability and agreement to comply with study procedures, in particular:

1. to adhere to conditions prior to test days

2. keep the habitual dietary habits and physical activity (except with regard to conditions prior to test days); however, the consumption of lactose-containing products between V1 and V2 should be encouraged

3. to complete study visits as required

4. to avoid the use of other products which may influence the GI complaints during the study

5. to avoid the use of lactase during the study

6. to complete the subject diary and study questionnaires (including the questions that require the use of the Visual Analogue Scale (VAS))

6. Women of childbearing potential:

1. commitment to use appropriate contraception methods

2. negative pregnancy testing (beta human chorionic gonadotropin test in urine)

7. Readiness not to participate in another clinical study during this study

Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Exclusion Criteria

1. Self-reported known allergy or hypersensitivity to any components of the investigational products and/or chlorhexidine and/or standardised on-site meal

2. Self-reported congenital lactase deficiency (CLD)

3. Self-reported galactosemia

4. Self-reported history and/or presence of relevant GI disease or digestion/absorption disorder (e.g. inflammatory bowel disease, coeliac disease, gastroenteritis, severe constipation etc.) except for irritable bowel syndrome ((IBS); this condition is acceptable)

5. Self-reported inexplicable weight loss (>5%) within the last 3 months prior to study

6. Pulmonary disease that may interfere with the HBT

7. Hospital Anxiety and Depression Scale (HADS) anxiety or depression score of ≥11 at V0

8. Patient Health Questionnaire for Somatization (PHQ-15) score ≥15 at V0

9. Self-reported history and/or presence of other clinically significant condition/disorder, which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:

1. uncontrolled thyroid gland disorder

2. uncontrolled hypertension

3. diabetes mellitus

4. immunodeficiency

5. scleroderma

6. any other relevant serious organ or systemic diseases (e.g. cardiovascular, liver, renal, malignant, psychiatric disease etc.)

10. Significant GI surgery (except cholecystectomy, appendectomy) within the last 6 months prior to or planned during the study

11. Smoking

12. Colonoscopy or colon cleaning procedure within the last 4 weeks prior to and during the study

13. Regular medication and/or supplementation within the last 4 weeks prior to and during the study:

1. antibiotics

2. probiotics

3. for management of LI complaints or any other that could influence gastrointestinal functions (e.g. laxatives (including fermentable dietary fibers), opioids, systemic corticosteroids, anticholinergics, anti-diarrheals, spasmolytics, prokinetics etc.) as per investigator judgement; intake of lactase prior to study is allowed

14. Clinically relevant deviation of safety laboratory parameter(s) at V0

15. Women of child-bearing potential: pregnancy or nursing

16. History of or current abuse of drugs, alcohol or medication

17. Participation in another study during the last 30 days prior to and during the study

18. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Analyze & Realize

NETWORK

Sponsor Role: collaborator

Novozymes A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Liana Vismane, MD

Role: PRINCIPAL_INVESTIGATOR

analyze & realize GmbH

Locations

Analyze & Realize Study Center

Berlin, , Germany

Countries

Germany

Other Identifiers

NOZ-DK/021121

Identifier Type: OTHER

Identifier Source: secondary_id

NZ-2021-11

Identifier Type: -

Identifier Source: org_study_id